New prostate cancer trial aims to cut fatigue with personalized drug plan

NCT ID NCT06274047

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This Phase 3 trial tests whether personalizing apalutamide treatment based on cancer aggressiveness can reduce fatigue and other side effects in men with prostate cancer who have detectable PSA after prostatectomy. About 120 participants will receive either standard therapy or a personalized apalutamide regimen alongside radiation and hormone therapy. The goal is to improve quality of life without compromising cancer control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Apalutamide and androgen deprivation therapy (ADT)
What this could lead to: If successful, this could lead to a more personalized treatment approach that reduces fatigue and other side effects for men with prostate cancer after surgery and radiation.
What could go wrong: This is a Phase 3 trial, but it is still experimental. The personalized approach may not improve quality of life as hoped, and side effects from apalutamide and ADT can still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGEN AXIS SUPPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANDROGEN AXIS SUPPRESSION PROSTATE CANCER PROSTATECTOMY

Contacts and locations

Locations

Banner MD Anderson
RECRUITING

Gilbert, Arizona, 85234, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Rush MD Anderson
RECRUITING

Chicago, Illinois, 60607, United States
University of Kansas Medical Center
RECRUITING

Kansas City, Kansas, 66103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.